Becton Dickinson and (NYSE:BDX) Now Covered by Analysts at KeyCorp

Analysts at KeyCorp assumed coverage on shares of Becton Dickinson and (NYSE:BDX) in a report issued on Friday, January 5th, MarketBeat reports. The brokerage set an “overweight” rating and a $260.00 price target on the medical instruments supplier’s stock. KeyCorp’s price target suggests a potential upside of 15.14% from the company’s current price.

Other analysts have also issued research reports about the company. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 target price on shares of Becton Dickinson and in a report on Tuesday, September 12th. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Morgan Stanley increased their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Zacks Investment Research lowered Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $230.20.

Shares of Becton Dickinson and (NYSE BDX) opened at $225.82 on Friday. Becton Dickinson and has a 52 week low of $169.19 and a 52 week high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $51,800.00, a P/E ratio of 48.56, a PEG ratio of 1.70 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the prior year, the company posted $2.12 earnings per share. Becton Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts forecast that Becton Dickinson and will post 10.89 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares in the last quarter. Harfst & Associates Inc. grew its stake in shares of Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd grew its stake in shares of Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 338 shares in the last quarter. Acrospire Investment Management LLC grew its stake in shares of Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after buying an additional 600 shares in the last quarter. Finally, Valeo Financial Advisors LLC acquired a new stake in Becton Dickinson and during the 3rd quarter valued at approximately $191,000. Institutional investors and hedge funds own 75.53% of the company’s stock.

WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/becton-dickinson-and-bdx-coverage-initiated-by-analysts-at-keycorp.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply